From the 1Department of Obstetrics and Gynecology, University Hospital of Oulu, Oulu, Finland; 2National Institute for Health and Welfare, Oulu, Finland; 3National Institute for Health and Welfare, Helsinki, Finland; 4Nordic School of Public Health, Gothenburg, Sweden; 5Sexual Health and Family Planning Clinic, City of Helsinki Health Centre, Helsinki, Finland; and 6Department of Obstetrics and Gynecology, Helsinki University Central Hospital, Helsinki, Finland.
Funding provided by Helsinki University Central Hospital Research Funds (to Drs. Suhonen and Heikinheimo), The Finnish Society of Obstetrics and Gynecology (to Dr. Niinimäki), and Schering Ag Finland (to Dr. Heikinheimo).
The authors thank Matti Kesti for his help in computing the data.
Corresponding author: Oskari Heikinheimo, Department of Obstetrics and Gynecology, Helsinki University Central Hospital, PO Box 140, 00029-HUS, Helsinki, Finland; e-mail: [email protected].
Financial Disclosure Dr. Suhonen has lectured at educational meetings organized by Bayer Schering (Leverkusen, Germany) and Shering-Plough (Kenilworth, NJ). Dr. Heikinheimo has been a paid consultant and lecturer for Bayer Schering Pharma and Schering-Plough. He also belongs to Bayer Schering Pharma's international and national advisory boards and has received travel and research grants from Bayer Schering Pharma and Nordic Drugs. The other authors did not report any potential conflicts of interest.
